Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating) – Equities researchers at SVB Leerink cut their Q1 2022 earnings per share (EPS) estimates for Zimmer Biomet in a report issued on Monday, April 18th. SVB Leerink analyst D. Antalffy now forecasts that the medical equipment provider will post earnings of $1.40 per share for the quarter, down from their prior forecast of $1.51. SVB Leerink currently has a “Outperform” rating and a $135.00 target price on the stock. SVB Leerink also issued estimates for Zimmer Biomet’s Q2 2022 earnings at $1.56 EPS, FY2022 earnings at $6.36 EPS and FY2023 earnings at $7.04 EPS.
Other equities analysts have also recently issued reports about the stock. UBS Group cut shares of Zimmer Biomet from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $172.00 to $130.00 in a research report on Wednesday, February 2nd. Mizuho lowered shares of Zimmer Biomet from a “buy” rating to a “neutral” rating in a research note on Monday, January 10th. Wells Fargo & Company lowered their price objective on shares of Zimmer Biomet from $124.00 to $111.00 and set an “underweight” rating on the stock in a research note on Tuesday, February 8th. JMP Securities reduced their target price on shares of Zimmer Biomet from $175.00 to $145.00 and set an “outperform” rating for the company in a report on Tuesday, February 8th. Finally, Truist Financial downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating and boosted their price objective for the company from $128.00 to $142.00 in a report on Wednesday, April 13th. Two research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and a consensus target price of $143.58.
Zimmer Biomet (NYSE:ZBH – Get Rating) last posted its quarterly earnings results on Monday, February 7th. The medical equipment provider reported $1.95 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.98 by ($0.03). The business had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a return on equity of 12.30% and a net margin of 5.12%. The business’s revenue for the quarter was down 2.3% on a year-over-year basis. During the same period last year, the company earned $2.11 EPS.
The company also recently announced a quarterly dividend, which will be paid on Friday, April 29th. Investors of record on Tuesday, March 29th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date of this dividend is Monday, March 28th. Zimmer Biomet’s dividend payout ratio (DPR) is 50.53%.
In other Zimmer Biomet news, VP Chad F. Phipps sold 35,149 shares of the business’s stock in a transaction that occurred on Thursday, March 17th. The stock was sold at an average price of $121.97, for a total value of $4,287,123.53. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.73% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Amplius Wealth Advisors LLC acquired a new position in Zimmer Biomet during the 4th quarter worth about $26,000. Widmann Financial Services Inc. purchased a new position in Zimmer Biomet during the 4th quarter worth approximately $28,000. FSB Premier Wealth Management Inc. acquired a new stake in Zimmer Biomet during the 4th quarter worth approximately $33,000. US Asset Management LLC acquired a new stake in Zimmer Biomet during the 1st quarter worth approximately $33,000. Finally, Paragon Capital Management Ltd acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at approximately $34,000. 89.02% of the stock is currently owned by institutional investors.
About Zimmer Biomet (Get Rating)
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T.
- Get a free copy of the StockNews.com research report on Zimmer Biomet (ZBH)
- 3 No-Brainer Stocks to Buy with $1000
- Rite Aid Stock is Getting Cheap Enough to Buy Here
- Analysts Reel In Netflix Targets Ahead Of Q1 Earnings
- MarketBeat Podcast: Making Money in the Red-Hot Housing Market
- Banking On Bank Of America
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.